Avenir Corporation’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-28,460
Closed -$137K 67
2023
Q4
$137K Hold
28,460
0.01% 61
2023
Q3
$206K Hold
28,460
0.02% 58
2023
Q2
$211K Sell
28,460
-150
-0.5% -$1.18K 0.02% 58
2023
Q1
$198K Sell
28,610
-21,004
-42% -$193K 0.02% 61
2022
Q4
$510K Hold
49,614
0.05% 44
2022
Q3
$903K Hold
49,614
0.1% 38
2022
Q2
$2.55M Hold
49,614
0.24% 30
2022
Q1
$3.65M Hold
49,614
0.29% 27
2021
Q4
$7.1M Hold
49,614
0.55% 25
2021
Q3
$10.3M Hold
49,614
0.86% 23
2021
Q2
$10.5M Hold
49,614
0.84% 23
2021
Q1
$9M Sell
49,614
-9,340
-16% -$1.86M 0.78% 24
2020
Q4
$6.57M Hold
58,954
0.63% 23
2020
Q3
$6.39M Sell
58,954
-20,165
-25% -$2.46M 0.67% 25
2020
Q2
$6.59M Sell
79,119
-27,346
-26% -$1.05M 0.75% 23
2020
Q1
$1.45M Buy
106,465
+1,000
+0.9% +$8.46K 0.2% 37
2019
Q4
$420K Buy
105,465
+49,865
+90% +$216K 0.04% 61
2019
Q3
$279K Buy
55,600
+44,300
+392% +$242K 0.03% 62
2019
Q2
$66K Buy
11,300
+365
+3% +$2.87K 0.01% 68
2019
Q1
$120K Buy
+10,935
New +$345K 0.01% 65
2016
Q4
Sell
-900
Closed -$37K 70
2016
Q3
$37K Hold
900
﹤0.01% 69
2016
Q2
$131K Hold
900
0.01% 64
2016
Q1
$93K Hold
900
0.01% 64
2015
Q4
$151K Hold
900
0.01% 69
2015
Q3
$127K Hold
900
0.01% 57
2015
Q2
$201K Hold
900
0.01% 57
2015
Q1
$149K Hold
900
0.01% 58
2014
Q4
$107K Hold
900
0.01% 59
2014
Q3
$75K Buy
900
+100
+13% +$9.04K 0.01% 65
2014
Q2
$74K Buy
+800
New +$70.3K 0.01% 69

Other funds holding NVAX

Avenir Corporation's NVAX Position: Q1 2024 in Review

Avenir Corporation sold out of Novavax (NVAX) in Q1 2024, closing a stake of 28,460 shares — an estimated $137K sold.

Avenir Corporation first reported a position in NVAX in Q2 2014 and held it in 30 quarters. The position peaked at $10.5M in Q2 2021. 202 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.

  • Avenir Corporation reported no remaining Novavax position as of Q1 2024 after selling out during the quarter.
  • Avenir Corporation sold 28,460 Novavax shares in Q1 2024, an estimated $137K.
  • Avenir Corporation first reported a position in Novavax in Q2 2014 and held it in 30 quarters.
  • Avenir Corporation's Novavax position peaked at $10.5M in Q2 2021.
  • 202 funds tracked by Wall St. Rank held Novavax as of Q1 2024.

Based on Avenir Corporation's 13F filing for Q1 2024, filed 16 May 2024.